Skip to main content
. Author manuscript; available in PMC: 2018 Jun 1.
Published in final edited form as: Cancer Res. 2017 Apr 4;77(11):3070–3081. doi: 10.1158/0008-5472.CAN-15-3052

Figure 6. BCL6 in a targetable vulnerability in a subset of NSCLC cell lines.

Figure 6

A. Quantitation of the fraction of cells with altered SMAD2/3 signaling in NSCLC cell lines H1693, H1819, H1993, HCC827 and H2009 compared to parental HBEC and parental HBEC treated with 10% FBS for 40 minutes (positive control) based on immunofluorescence microscopy. Error bars (n = 7 technical replicates) as in Fig. 1C.

B. Relative BCL6 gene expression from qRT-PCR assay of NSCLC cell lines transfected with non-target control and Omomyc construct compared to the level in parental HBEC (horizontal dotted line). Error bars and p-values are as in Fig. 3B (n = 6 technical replicates).

C. Protein expression of BCL6 and phospho-STAT3 in NSCLC cell lines H1693, H1819, H1993, HCC827 and H2009 compared to parental HBEC as measured by western blot. GAPDH is used as a loading control.

D. Relative viability of NSCLC cell lines H1693 and H1993 compared to H2009 after siRNA mediated BCL6 knockdown. Error bars and p-values are as in Fig. 3B (n = 2 technical replicates).